Thrombosis Associated with Cancer Market
Number of pages: 100 | Report Format: PDF | Published date: 27 January, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 8.9% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments covered |
Drug class, Indication and Region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global thrombosis associated with cancer market shall grow at a CAGR of 8.9% during the forecast period from 2022 to 2030.
Market Fundamental
Cancer thromboembolism can range from arterial or venous thromboembolism to disseminated intravascular coagulation. Despite the well-known link between cancer and thromboembolic disorder, the processes promoting thromboembolic events in cancer patients are not fully understood and appear complex. Cancer patients are commonly hypercoagulable or prothrombotic, as they have abnormalities in all three components of Virchow's triad, which contribute to thrombosis. Furthermore, cancer cells can trigger the coagulation cascade and other prothrombotic features of host cells. Thrombotic complications in cancer can vary from arterial or venous thromboembolism to disseminated intravascular coagulation. Low‐molecular‐weight heparin (LMWH) compared to warfarin, has been shown to reduce the risk of recurrent VTE in patients with thrombosis associated with cancer and is therefore the standard treatment for acute thrombosis associated with cancer for the past 15 years.
Trousseau's syndrome (cancer-associated thrombosis) is the second largest cause of death among cancer patients following cancer death. Patients with cancer have a 4- to 7-fold increased risk of venous thromboembolism compared to individuals who do not have cancer. The causes of this poor coagulation are associated with general patient-related risk factors as well as cancer-specific or treatment-specific variables. Furthermore, cancer-related thrombosis presents clinically as deep vein thrombosis (DVT), pulmonary embolism (PE), chronic DIC linked with NBTE, and arterial thrombosis. Secondary thrombotic episodes associated with chemotherapy or central venous catheterization are sometimes described as cancer-associated thrombosis. As a result, the incidence of cancer-related thrombosis varies greatly between studies, depending on the patient population.
Market Dynamics
Cancer is associated with an increased incidence of venous thromboembolism (VTE) (4% to 20%) and arterial thrombosis (2% to 5%). VTE is the second greatest cause of death in the cancer community, closely behind cancer itself. Cancer patients have a four to sevenfold increased risk of VTE and a twofold increased risk of significant hemorrhage on anticoagulation compared to individuals without cancer. Cancer patients' quality of life may be impacted by VTE and its treatment, which can also have other negative effects including bleeding or recurring VTE. Consequently, the most effective VTE prevention and therapy are essential elements of patient care in this population. Furthermore, the growing global oncology burden caused by increased alcohol and tobacco consumption is propelling the global thrombosis associated with cancer market forward. In its report GLOBOCAN, the International Agency for Research on Cancer (IARC) stated that around 19.3 million new cancer cases and nearly 10 million cancer-related deaths were registered globally in 2020. According to the IARC, new cancer cases are anticipated to climb by 47% globally between 2020 and 2040.
Market Ecosystem
The global thrombosis associated with cancer market has been analysed from three perspectives by drug class, indication and region.
Thrombosis Associated with Cancer Market by Drug Class
[24214]
Based on drug class, the global thrombosis associated with cancer market by drug class has been segmented into heparin, vitamin k antagonist, factor Xa inhibitors, direct thrombin inhibitors. the heparin is sub segmented into low molecular weight heparin (LMWH), unfractionated heparin (UFH). The heparin segment dominated the market during forecast period because of its potent anticoagulant effect, heparin is used to prevent and treat venous thromboembolism in cancer patients. Anticoagulant therapy with heparin appears to improve prognosis and survival in individuals with diversiform tumours, according to clinical research. Heparin is a complex mixture of naturally occurring GAG extracted from pig intestine that is typically produced as a sodium salt. Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are the two forms of heparin, with the latter comprising a number of subtypes such as enoxaparin, nadroparin calcium, dalteparin sodium, and tinzaparin. Many different forms of heparin have been synthesised as a result of the advancement of current biosynthetic processes, with certain heparin chemical groups being added or replaced.
Thrombosis Associated with Cancer Market by Indication
Based on indication, the global thrombosis associated with cancer market by drug class has been segmented into venous thromboembolism, arterial thrombosis. The venous thromboembolism dominated the market during forecast period. Venous thromboembolism (VTE), the most common clinical manifestation of cancer-related thrombosis, encompasses both deep vein thrombosis (DVT) and pulmonary embolism (PE). It has been observed that it affects 4-20% of cancer patients. In contrast, 20% of individuals with symptomatic DVT had an active cancer. It has been found that the risk of VTE is four to seven times higher in cancer patients than in non-cancer patients.
Thrombosis Associated with Cancer Market by Region
Based on region, the global thrombosis associated with cancer market by drug class has been segmented into North America, Europe, Asia Pacific, and Rest of the World. The North America dominated the market during forecast period. The growth of the market in the region is characterized by rising disease prevalence and need for treatment, together with rising disease diagnosis and adoption of cutting-edge therapies. The area holds a significant share of the global market due to these reasons, as well as the patient population's increased healthcare expenditures toward novel treatment alternatives and the presence of major businesses with their pipeline candidates and planned launches.
During the forecast period, Europe is expected to be the most opportunistic market. This is due to increasing technical improvements in the diagnosis of many cancers. Furthermore, the rising prevalence of cancer in Europe, as well as the increasing number of cancer fatalities, are likely to fuel the expansion of the Europe thrombosis associated with cancer market in the coming years.
Competitive Landscape
Some of the prominent market player in the global thrombosis associated with cancer market include:
Strategic Development
The Europe is the key growth region in the global thrombosis associated with cancer market.
The rising incidence of cancer globally, number of initiatives undertaken by government and other organizations to spread disease awareness and technologic advancements in developed countries.
Some of the prominent players operating in the global thrombosis associated with cancer market are GSK plc., Janssen Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited., Bristol-Myers Squibb Co., Sanofi-Aventis U.S. LLC., LEO Pharma, Pfizer Inc., Boehringer Ingelheim International GmbH., Anthos Therapeutics, Lonza, Bayer AG, Amphastar Pharmaceuticals, Inc. among others.
The venous thromboembolism segment led the global thrombosis associated with cancer market.
Cancer thromboembolism can range from arterial or venous thromboembolism to disseminated intravascular coagulation. Despite the well-known link between cancer and thromboembolic disorder, the processes that promote thromboembolic events in cancer patients are not fully understood and appear to be complex. Cancer patients are commonly hypercoagulable or prothrombotic, as they have abnormalities in all three components of Virchow's triad, contributing to thrombosis.
*Insights on financial performance are subject to availability of the information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst